[Cheddar] Abraham Heifets, Co-founder & CEO of Atomwise joins Cheddar to discuss the company’s recent funding round and it’s coronavirus-related projects.
[Drug Target Review] According to a new report, artificial intelligence (AI) is vital for the rapid identification of drugs that can be repurposed to combat COVID-19.
[AiThority] Recently, a news report suggested that a team of AI scientists have made a belligerent effort to identify hundreds of new drugs as a potential COVID-19 therapy. COVID-19 is caused by the novel coronavirus, SAR COV-2, whose origins have been speculated to be a wet market in Wuhan in China. AI engineers and pharmaceutical companies are […]
Drug discovery startup Atomwise and stroke risk predictor Viz.ai are among a group of seven healthcare companies recognized by Forbes for their artificial intelligence capabilities.
As Covid-19 continues to threaten lives and livelihoods around the world, a great emphasis has been put on preventing and treating the disease. However, putting a human drug through the FDA approval process costs hundreds of millions of dollars and takes months, if not years, of clinical trials. What if one of the over 7,800 […]
The University of Kentucky (UK) has announced a research collaboration with Atomwise to explore potential COVID-19 therapies. An associate professor in UK’s college of medicine was granted the project from Atomwise’s Artificial Intelligence (AI) Molecular Screen award program, which seeks to democratize access to AI for drug discovery and enable researchers to accelerate the translation of their research into novel […]